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Abstract
Background: Metabolite profiles can be used for identifying molecular signatures and mechanisms underlying
diseases since they reflect the outcome of complex upstream genomic, transcriptomic, proteomic and
environmental events. The scarcity of publicly accessible large scale metabolome datasets related to human disease
has been a major obstacle for assessing the potential of metabolites as biomarkers as well as understanding the
molecular events underlying disease-related metabolic changes. The availability of metabolite and gene expression
profiles for the NCI-60 cell lines offers the possibility of identifying significant metabolome and transcriptome
features and discovering unique molecular processes related to different cancer types.
Methods: We utilized a combination of analytical methods in the R statistical package to evaluate metabolic
features associated with cancer cell lines from different tissue origins, identify metabolite-gene correlations and
detect outliers cell lines based on metabolome and transcriptome data. Statistical analysis results are integrated
with metabolic pathway annotations as well as COSMIC and Tumorscape databases to explore associated
molecular mechanisms.
Results: Our analysis reveals that although the NCI-60 metabolome dataset is quite noisy comparing with
microarray-based transcriptome data, it does contain tissue origin specific signatures. We also identified biologically
meaningful gene-metabolite associations. Most remarkably, several abnormal gene-metabolite relationships
identified by our approach can be directly linked to known gene mutations and copy number variations in the
corresponding cell lines.
Conclusions: Our results suggest that integrative metabolome and transcriptome analysis is a powerful method for
understanding molecular machinery underlying various pathophysiological processes. We expect the availability of
large scale metabolome data in the coming years will significantly promote the discovery of novel biomarkers,
which will in turn improve the understanding of molecular mechanism underlying diseases.
Background
Metabolites are end products of cellular processes. Thus
the profile of metabolites provides a snapshot of the phy-
siological state of a cell complementary to its transcrip-
tome and proteome, which manifests the functional status
of events which occur more upstream. Since the size of
metabolome is about 1-2 orders of magnitude smaller
than transcriptome and proteome, the steady state con-
centration of a metabolite usually reflects the combined
effects of multiple upstream factors. Conceivably, this
property makes metabolites better biomarkers in some
situations. In addition, identifying interrelations between
metabolites and genes, proteins, or genome structures can
potentially facilitate the elucidation of molecular mechan-
isms involved in pathophysiological processes.
Previous work has revealed significant associations
between gene and metabolite expression profiles, which
added another layer of quantitative inferences to gene-
wise correlations [1-3]. Nam et. al demonstrated that the
* Correspondence: sugang@umich.edu; mengf@umich.edu
1Bioinformatics Program, University of Michigan, Ann Arbor, MI 48109, USA
4National Center for Integrative Biomedical Informatics, University of
Michigan, Ann Arbor, MI 48109, USA
Full list of author information is available at the end of the article
Su et al. BMC Bioinformatics 2011, 12(Suppl 1):S36
http://www.biomedcentral.com/1471-2105/12/S1/S36
© 2011 Su et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
integrative study of transcriptomics and metabolomics
could effectively identify metabolic biomarkers for breast
cancer [4]. Nevertheless, the noisy nature of the metabo-
lome data, limited number of metabolites with known
structures in metabolome data, the lack of annotation of
metabolite-gene relationships despite databases like
EHMN and BiGG [5,6], the indirect nature of potential
gene-metabolite relationships, and the lack of large scale
metabolome study data in the public domain, still limit
our knowledge of metabolites and their regulation in nor-
mal and disease processes.
Conceivably, cancer samples provide excellent oppor-
tunities for identifying metabolic biomarkers and gene-
metabome relationships due to the dramatic function
alterations at the molecular level in cancer tissues. For
example, cancer tissues usually exhibit more than 10-
fold changes in the expression level of many genes in
numerous microarray studies. Recently, the collabora-
tive NCI60 project from the Developmental Therapeu-
tics Program (DTP) of the National Cancer Institute
(NCI) has made extensive measurements of various
‘omics’ data publicly available, including microarray,
metabolomics, proteomics, etc. While the number of
metabolome of metabolome-related studies and bio-
marker discoveries associated with cancer is increasing
rapidly in targeted studies, there is still no literature
on comprehensive analysis of metabolic features and
their regulatory mechanisms of different cancer types
across multiple ‘omics’ data.
In this study, we want to investigate whether different
cancer cell lines have distinct metabolic signatures and
whether available metabolome data for the NCI-60 cell
lines is suitable for cancer subtype classification. We
also hope the combined metabolome and transcriptome
analysis will reveal some distinct regulatory relationships
in some of the NCI-60 dataset which are not otherwise
possible by either metabolome or transcriptome study
alone. We expect the analysis approach used in this
work can be applied to other metabolome-transcriptome
datasets when they become available.
Results
Metabolomic signature of cancer cells from different
tissue origins
The first question we would like to address is whether
cancer cell lines exhibit tissue-origin specific metabolic
signatures. We used classification analysis similar to
those performed in microarray data [7] to classify 57
cell-lines into 9 cancer types related to their tissue ori-
gins. Our initial tests suggest that regardless of method
used, the classification error on metabolomics data is
always significantly higher than that from microarray
(~0.51 for metabolomics and ~0.34 for microarray).
Besides the fact that NCI-60 metabolome dataset has
much less data points but with higher noise levels when
compared to microarray data, we speculate that the low
number of some cancer types (e.g. only 2 prostate
cancer cell lines) and high heterogeneity of some cell
lines (breast, ovarian and CNS) may also undermine the
performance of the metabolome-based classification. In
fact, these 4 cell lines contribute most to the out of bag
classification error estimates.
After prostate, breast, ovarian and CNS cell lines are
removed from the whole sample, the metabolite classi-
fiers can reach comparable performance with microarray
classifiers (Figure 1). The significantly improved metabo-
lome-based classification results after removing cell lines
with high variability or heterogeneity strongly suggests
that there are indeed cancer subtype-specific (based on
tissue of origin) metabolic signatures.
Since the removal of cancer classes will also reduce
the complexity of the data thus naturally improve classi-
fication performance, we also removed the same number
of cancer classes at each stage randomly for 500 times
to estimate the effect of improvement of OOB errors
due to simplification of data structure resulted from
sample removal (orange dashed lines in Figure 1). It can
be seen that the reductions in OOB errors from random
removal are not as significant as those from progres-
sively removal of the prostate, breast, ovarian and CNS
cell line classes, suggesting that it is indeed the high het-
erogeneity and the low sample number of these cell line
classes that caused the high OOB error in the original
classification. Consequently, our results suggest that
although metabolite profiles are not as good as microar-
ray data for the classification of cancer cell lines, meta-
bolites nonetheless contain cell type specific signature
and the classification results can be improved if we have
more samples or have more data points in the metabo-
lome assays.
Correlation analysis
Although existing metabolome data do not outperform
microarray data in cell line subtype classification, metabo-
lome can still be useful for revealing some basic molecular
processes and their alterations in NCI-60 cell lines. We
hypothesize that different cell lines should share some
basic regulatory and metabolic processes (steady-state)
essential for cell growth and metabolism. It is likely that
although different cancer cell lines may have very different
levels of gene expression and metabolism, the steady-state
relationship between genes and metabolites in the same or
highly coupled pathways should be conserved across differ-
ent cell lines in the absence of dramatic genomic changes
such as gene mutation and copy number variation (CNV).
Identification of such gene-metabolite relationships at
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steady state will help us better understand the underlying
molecular mechanisms related to the metabolic change.
They will also help us infer potential metabolic changes
based on the expression data or vice versa. On the other
hand, if a few cell lines deviated significantly from the
gene-metabolite relationships exhibited by the most of the
cell lines, the related genes in such outlier cell lines are
likely to be silenced (no expression) or agitated (over
expression) due to genomic structural changes. Conse-
quently, we are interested in both high correlations which
reflect steady state trend over all samples, and outliers
which reflect signatures in specific cell lines.
The classic method of inspecting the relatedness of
two quantitative features is by computing the Pearson
Correlation Coefficient (PCC). While PCC have been
proven to work well in many gene expression studies,
the correlation is often inflated by outliers or clustering
effect, which made it not suitable to analyze data with
high noise level such as metabolic profiles. In contrast,
the robust correlations can provide a much better esti-
mate of the true association in the presence of multi-
dimensional outliers if the sample size is sufficiently
large. We chose the Pair-wise Quadrant Correlation
(PQC) for its good computational performance. How-
ever, for small sample size, PQC sometimes may inflate
the correlation estimate. Therefore our correlation ana-
lysis, we use a novel approach by combining results
from both PCC and PQC. Gene-metabolite pairs with
high PCC and high PQC tend to demonstrate true linear
correlation across all cancer types, which imply a gen-
eral functional association between gene and metabolite
profiles. On the other hand, gene-metabolite pairs with
high PCC and low PQC are possibly resulted from a few
extreme outliers, which can potentially be linked to cell-
line specific signatures.
Metabolite-gene correlations
Since metabolite-gene relationships can help us to
understand the direct or indirect cause of metabolite
changes, we computed PCC and PQC for 11872 gene
expression profiles and 253 metabolite measurements
over 57 cell-lines.
To investigate the biological significances of the
correlation analysis, we mapped all the known gene-
compound associations from EHMN to our NCI60
analysis. There are a total of 721 EHMN annotated
direct metabolite-gene associations, involving 352 genes
and 81 known metabolites, that overlap with our NCI-
60 metabolite-gene relationships.
Figure 2 shows a mapping of our current metabolite-
compound knowledgebase to the robust correlations.
We chose the top 9 pathways in EHMN mapping
ordered by number of genes
Some of the EHMN gene-compound relationships do
show high association across all cell-lines. For example,
gene AKR1B1 which reduces L-Arabitol to L-Arabinose
Figure 1 Classification error. Estimated Out-of-Bag (OOB) Error with regard to progressive cancer class removal. At each step, cancer classes
contribute most to classification error were removed and OOB errors were recalculated. B: Breast Cancer. P: Prostate Cancer. O: Ovarian Cancer.
C: CNS. The left plot shows OOB errors on entire dataset and the right plot shows OOB errors on subset of classifiers selected by varSelRF. The
improvement of variable selection is more remarkable for microarray because of the much larger classifier pool to select from (11961 v.s. 342).
Metabolite classifiers can achieve average OOB error of 0.28 when B,P,O,C are removed, reduced from 0.51 from the full set. The OOB error for
u133a reduced from 0.34 to 0.18. The average OOB errors from the random cancer class removal are plotted in the orange dashed line.
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with EHMN reaction ID R01758 and R01759, is asso-
ciated with L-Arabitol with PQC of 0.69 and PCC of
0.36, which implies strong association between metabo-
lite level and gene activity. However, it is surprising that
most of the direct enzyme-metabolite relationships can-
not be mapped to high correlations (Figure 2A and 2B).
There are several possible explanations to the low
match-ups of significant correlations to EHMN data.
A simple explanation is most of the annotatable gene-
metabolite relationships in the NCI-60 dataset may not
be the speed limiting factor in the related pathways. It is
also possible that the high level of abnormal regulation
in the cancer cell lines may have masked global
mechanisms such that it is difficult to identify high gene
to metabolite correlations across all cell lines.
Interestingly, the grouping of genes in the same path-
way in Figure 2 enables us to detect many metabolites
exhibit high correlations with other genes in the same
pathway. For example, although phosphoenolpyruvate
does not overlap with any of the EHMN annotated direct
reaction genes in Figure 2B, it has high correlation with
GPI and ALDOA, two of the genes in the glycolysis mod-
ule that are known to be highly regulated by hypoxia-
inducible factor 1alpha and such regulation is related to
the aggressive phenotype of hepatocellular carcinoma.
Consequently, ALDOA, GPI and other genes highly cor-
related with phosphoenolpyruvate in our multi-cancer
cell line analysis may suggest that these genes has more
significant regulatory or speed limiting roles in glycolysis
than genes such as ENO1, ENO2 that are directly related
Figure 2 Heatmap of gene-metabolite relationship organized according to KEGG pathway. Mapping of EHMN gene-metabolite
association data to robust correlation matrix heat map. A. Rows are genes grouped by pathway names, columns are metabolites also grouped
by corresponding pathway names. Green circles mark the position of a specific reaction that couples a metabolite and a gene from EHMN.
Orange Light cells indicate positive PQC, with black to be 0 and orange to be 1. It can be seen that even though there are patterns of gene-
metabolite clustering, very few high correlations can be mapped to known reactions. B. Gene-metabolite correlation in the Glycolysis pathway. C:
The gene-gene correlation with in Glycolysis pathway.
Su et al. BMC Bioinformatics 2011, 12(Suppl 1):S36
http://www.biomedcentral.com/1471-2105/12/S1/S36
Page 4 of 7
to reactions involving phosphoenolpyruvate in these
cancer cell lines. Naturally, not all genes in the same
pathway strongly correlate with each other since genes in
the same pathway are not all (Figure 2C).
Further investigation will be worthwhile for high cor-
relation between metabolites and other genes (i.e. those
not directly involved in the specific metabolic reaction)
in the same pathway, as such un-annotated relationships
are likely help us to identify speed limiting enzymes in a
pathway, key regulatory genes of related pathways or
novel metabolic mechanisms.
Outlier analysis
In our previous analysis we require high PQC in addi-
tion to high PCC to identify molecule pairs with true
high correlation. We have also identified many cases
where cell lines have one or a few gene-metabolite pairs
with much higher expression values than the rest of the
other samples, which directly produce inflated PCC and
very low PQC. To systematically investigate these cases,
we used R package mvoulier to detect multidimensional
outliers, and recomputed the PCC and PQC scores after
outlier removal. Our empirical rule shows that when
PCC > 0.6 and PQC < 0.3(Preferably close to 0), and the
number of multidimensional outliers is smaller than 3,
the high PCC is most likely to be an artifact from very
few extreme outliers.
To explore the biological significance of these outliers,
we compared the outlier cases detected by the criteria
mentioned above to the Sanger Cosmic database [8].
Sanger Cosmic contains 177 mutation entries of 28
genes in our 57 NCI60 cell-lines. We ordered all the
metabolite-gene correlations of the 28 genes by PCC,
and amazingly the top two outliers detected by our
approach, NOTCH1~X-2005 in MOLT-4 cell line and
KRAS~in X-2690 in OVCAR-5 cell line, are the cell
lines with known gene mutation on the exact same
genes in Sanger Cosmic database (Figure 3).
The common feature of these two gene-metabolite
pairs is high PCC and low PQC before outlier removal
and low PCC and low PQC after the outlier removal.
From plots in Figure 3 we can verify that the inflated
PCC were indeed a product of single cell line outlier.
Besides, the sample sizes of these two cases are suffi-
ciently large (22 for NOTCH1~X-2005 and 26 for
KRAS~X-2690, respectively) so that the outlier is not
likely to be a random fluctuation from small sample
size.
Since our unbiased analysis did not take advantage of
any cell line or gene mutation information, the fact that
our top two outliers overlaps with documented gene
mutation in the Sanger Cosmic dataset suggests that the
mutations are likely to be a cause of such outliers, and
the associated metabolites may be good candidate bio-
markers for such events.
In addition to point mutations, we also compared the
outlier analysis with Copy Number Variation (CNV)
data from Broad institute. Only 34 out of 57 samples
from NCI60 have CNV data, and also found some gene-
metabolite outlier pairs that are consistent with CNV
outliers. For example, gene BRIP1, with CNV of 14.22
in cell line MCF7, has PCC of 0.90 and PQC of 0.008
and one outlier. The corresponding compound, X-3363,
may be associated specifically to this copy number
variation.
The fact that some top ranked gene-metabolite outlier
associations matches with known corresponding geno-
mic structural changes in the specific gene strongly sug-
gests the effectiveness of our approach in identifying
distinct molecular processes specific to metabolome and
transcriptome variations.
Methods
NCI-60 data pre-processing: raw molecular datasets
were downloaded from DTP web portal (http://dtp.nci.
nih.gov/index.html March 2007 release). There are 57
cell-lines in 9 cancer classes have both microarray and
metabolomics data. We used our in-house Entrez-based
Custom CDF version 12 to derive gene-level expression
data from the NCI-60 Affymetrix Genechip CEL files
(http://brainarray.mbni.med.umich.edu) [9]. The meta-
bolite data averaged over triplicate experiments were
manually compared with a reference dataset to exclude
imputed values (Beecher, unpublished data) as the
imputed data could significantly bias the inferences
drawn from correlation analysis. All metabolite names
were manually compared with KEGG and assigned a
KEGG compound ID whenever possible. The pre-pro-
cessing step produced 11961 and 6089 gene expression
profiles from Affymetrix HG-U133A and HG-U133B
chips respectively, and quantitative data for 124 known
and 218 unknown metabolites.
All statistical analyses were performed in R (http://
www.r-project.org/). Classification and variable selection
were performed by R randomForest (http://cran.r-
project.org/web/packages/randomForest/index.html) and
varSelRF package [10]. The robust correlations were
computed with robust package (http://cran.r-project.org/
web/packages/robust/index.html), using the parameter
pair-wise Quadrant Correlation (pairwiseQC). Multidi-
mensional outliers were identified by package mvoutlier
[11]. We performed the computation on our LINUX
cluster of ~100 cores. The results were loaded into an
Oracle database for integrative analysis.
The annotated gene to metabolite relationship data
kindly offered by Edinburgh Human Metabolic Network
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project is used for identifying biological relevant known
gene-metabolite relationships revealed by our analysis
[5]. We also compiled a local version of KEGG [12] and
DAVID 2008 [13] for similar purposes. In order to
associate known mutations and CNVs in NCI-60 cell
lines to abnormal gene-metabolite relationships, we have
built a local copy of COSMIC [8] dataset from Sanger
and Tumorscape [14] from Broad institute for cell-line
specific point-mutation and copy number variations
(CNV), respectively.
Discussion
Our analysis results on the NCI-60 metabolome and
transcriptome data suggest that 1) although the small
sample size, the high noise level and intra-cancer class
heterogeneity in the current NCI-60 metabolome dataset
makes it unsuitable for global cancer subtype classifica-
tion, there are indeed metabolic signatures associated
with cancer subtypes. 2) There are biologically meaning-
ful high correlation gene-metabolite pairs across NCI-60
cell lines, identifiable by robust correlation estimates.
3) Most strikingly, there are several examples of abnor-
mal gene-metabolite coupling that can be directly linked
to known gene mutations or copy number variations.
Conceivably, high correlations as well as outliers can
be utilized to aid the progressive prediction of unknown
metabolites based on annotations in existing pathway
databases and literature. For example, the high correla-
tion of an unknown compound with a known gene and
in particular, multiple known genes in a pathway can
dramatically reduce the search space for the unknown
compound, since the most likely candidates will be
structurally related molecules or known metabolites
from related pathways. We plan to compare the Mass
Spectrometer (MS) features of these unknown com-
pounds from the predicted candidate pool and conduct
wet-lab experiments for validation. Since we have dis-
covered that many unknown metabolites are strongly
associated with each other but not with any known
compounds. Correct determination of even a small frac-
tion of them would facilitate the identification of the
rest, which also will in turn improve our understanding
of the molecular processes and pathways involving these
molecules.
In summary, the strong biological relevance of our
results also suggest that the analysis strategy we devel-
oped based on the combination of PCC and PQC corre-
lation values for identifying real correlation and true
Figure 3 Outlier analysis. Outlier analysis shows extreme gene-metabolite pairs could be resulted from cell specific mutations. Top scatter
plots: NOTCH1 ~ X-2005, with outlier in cell line MOLT_4 and KRAS ~ X-2690, with outlier in OVCAR5. It can be seen that the high PCC were
both artefacts of extreme outliers. Middle table: PCC and PQC of the corresponding pairs, before and after outlier removal. R_QC: PQC.
R_QC_RM: PQC after outlier removal. P_Pearson: PCC. R_P_RM: PCC after outlier removal. Bottom table: annotated mutation records from Sanger
Cosmic database, directly matched to these two outlier pairs.
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outliers is a powerful approach for integrative analysis of
noisy ‘omics’ datasets. The presentation of gene-metabo-
lite relationship analysis results in a heatmap grouped
by genes in the same pathway together with overlay of
known gene-metabolite relationship provides a powerful
visual exploration approach for identifying both direct
and indirect gene-metabolite relationships. The analysis
methods we described here will be useful for other inte-
grated analysis of metabolome and transcriptome
and the wet lab validation of novel gene-metabolite
relationships.
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